U.S. Cotton Trust Protocol Confirmed as ISEAL Community Member
23.6.2022 10:00:00 EEST | Business Wire | Press release
The U.S. Cotton Trust Protocol was accepted as an ISEAL Community Member following a rigorous and meticulous approval process and only eighteen months after the program’s launch.
ISEAL is a global membership organization that supports credited sustainability systems in their work, with the goal to drive greater impact and establish markets that are a force for good. The organization focuses on a wide variety of global challenges such as the climate emergency, biodiversity crisis and human rights issues among others. ISEAL works to define credible practices for sustainability, foster collaboration and shared experience, deliver expertise and training, and promote innovation to strengthen sustainability systems.
“I’m very happy to congratulate the U.S. Cotton Trust Protocol on becoming an ISEAL Community Member,” said Karin Kreider, ISEAL’s Executive Director. “The Trust Protocol supports cotton producers to develop bespoke management plans aimed at improving their sustainability, and innovative use of data and metrics supports measurement of success over time. We are excited to have a fresh perspective in the ISEAL learning community, and to have another member working to improve sustainability outcomes in the cotton sector.”
ISEAL Community Members must be committed to continually improving their systems through learning and innovation, with emphasis on the importance of collaboration. They also are required to be transparent about how their programs’ work and how they measure impacts.
The Trust Protocol is the only fiber sustainability system that provides quantifiable, verifiable goals and measurement and drives continuous improvement in six key sustainability metrics - land use, soil carbon, water management, soil loss, greenhouse gas emissions, and energy efficiency. It also is the world’s first sustainable cotton fiber to offer its members article-level supply chain transparency through the Protocol Consumption Management Solution.
“We are proud that the Trust Protocol was accepted as an ISEAL Community Member understanding the rigorous process and governance ISEAL adheres to,” said Dr. Gary Adams, president of the U.S. Cotton Trust Protocol. “ISEAL Community membership provides the Trust Protocol the continued opportunity to set a new standard in more sustainable cotton production where full transparency is a reality and continuous improvement to reduce our environmental footprint is the central goal.”
The U.S. Cotton Trust Protocol is aligned with the UN Sustainable Development Goals, recognized by Textile Exchange and Forum for the Future, and part of the Sustainable Apparel Coalition, Cotton 2025 Sustainable Cotton Challenge, Cotton 2040 and Cotton Up initiatives. It has also been recognized and published in the ITC Standards Map and recognized as a standard for sustainable cotton by the Partnership for Sustainable Textiles.
To learn more about the U.S. Cotton Trust Protocol visit TrustUSCotton.org.
About the U.S. Cotton Trust Protocol
Launched in 2020, the U.S. Cotton Trust Protocol was designed to set a new standard in more sustainably grown cotton, ensuring that it contributes to the protection and preservation of the planet, using the most sustainable and responsible techniques. It is the only farm level, science-based program that provides quantifiable, verifiable goals and measurement in six key sustainability metrics as well as article-level supply chain transparency.
The Trust Protocol is overseen by a multi-stakeholder Board of Directors comprised of representatives from brands and retailers, civil society and independent sustainability experts as well as the cotton-growing industry, including growers, ginners, merchants, wholesalers and cooperatives, mills and cottonseed handlers.
About ISEAL
ISEAL supports ambitious sustainability systems and their partners to tackle the world’s most pressing challenges. With a focus on credible practices, we advance scalable and effective solutions that make a lasting impact. Through our work to drive collective efforts, we make markets a force for good.
Find out more about ISEAL.
Visit us online at TrustUSCotton.org.
Follow us at:
https://twitter.com/trustuscotton
https://www.facebook.com/trustuscotton/
https://www.instagram.com/trustuscotton/
https://www.linkedin.com/company/responsibleuscotton/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005067/en/
Contact information
Media: Andrea Miles, andrea.miles@hkstrategies.com, +1 (213) 400-8267
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DCX builds coolant chemistry control into its 8 MW Facility Distribution Unit19.10.2026 15:01:00 EEST | Press release
Today DCX Liquid Cooling Systems announced worldwide’s first CDU system with built-in coolant control and treatment system. DCX integrated this coolant quality feature into it’s Facility Coolant Distribution Units: a family of 5-8 MW capable hyperscale-class coolant Distribution Units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014488003/en/ DCX announces the world’s first CDU with built-in coolant quality control and treatment - a new safety standard for hall-scale Liquid Cooling in critical AI infrastructure. The FDU monitors the chemistry of its coolant continuously and corrects it automatically with integrated electronic dosing pumps, supplying inhibitors, biocides and PH control additives. Hyper scale datacenters require new type of cooling solutions. In today’s liquid-cooled data centers, coolant quality and water treatment is becoming a rising issue. Left unmanaged, chemistry drift quietly takes away cooling pe
STARTEEPO Sends Letter to Xerox Board in Advance of Third-Quarter Earnings19.10.2026 15:00:00 EEST | Press release
STARTEEPO SICAV a.s. (“STARTEEPO”), which beneficially owns 7.34% of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX) in stocks and options, today issued the following letter to the Xerox Board of Directors (the “Board”): October 19, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Our open letter to the Board in early September helped spark a lively conversation about the future of this iconic company among investors and throughout the print industry. Despite these efforts, Xerox’s share price still does not reflect the significant value we see in the Company, a gap recently confirmed by Citi’s downgrade of Xerox stock to reflect the challenge of executing in “a structurally challenged print market.” Since our September letter, we’ve continued to actively engage with Xerox, including at the recent PRINTING United Expo in Las Vegas, and our conversations have been encouraging. We greatly appreciate the willin
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data include an oral proffered paper presentation on BeOne’s GPC3x4-1BB bispecific antibody, currently being studied in hepatocellular carcinoma (HCC) and first-in-human data for two investigational lung cancer assets, a CEA targeting antibody-drug conjugate (ADC), in CEA-expressing non-small cell lung cancer (NSCLC), and a brain-penetrant PRMT5 inhibitor in MTAP-deleted tumors, inclu
The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Experts in Vienna19.10.2026 13:00:00 EEST | Press release
Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent challenge: transforming Europe's data centre energy landscape. We brought together leaders from across the data ce
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO ® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 12:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically relevant target in the treatment of moderate to severe ulcerative colitis.1 Results were presented during late-breaker and poster sessions at United European Gastroenterology (UEG) Week 2026 and published in the United European Gastroenterology Journal. “There has been increasing conversation about whether achieving deeper levels of remission – addressing both visible and microscopic inflammation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
